View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 24, 2011

Prana given clearance to begin Alzheimer’s drug trial

The Austin Health Research Ethics Committee has granted approval to Prana Biotechnology to initiate a 12-month Phase II Imaging trial in Australia to evaluate PBT2, an Alzheimer's drug.

The Austin Health Research Ethics Committee has granted approval to Prana Biotechnology to initiate a 12-month Phase II Imaging trial in Australia to evaluate PBT2, an Alzheimer’s drug.

The double-blind and placebo-controlled trial will enrol 40 patients with prodromal or mild Alzheimer’s disease, and measure physical changes in the brains over 12 months of treatment with PBT2

The results will also be used to assess the positive effects of PBT2 on cognition reported in the earlier study.

In this study, cognition effects will be measured by the Neuropsychological Test Battery.

Prana executive chairman Geoffrey Kempler said, ”We believe that in this 12-month trial PBT2 will establish its credentials as a safe and effective treatment for Alzheimer’s disease,” Kempler added.

The trial has been funded by the Alzheimer’s Drug Discovery Foundation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU